Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
Type
IgG2 - kappa
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in ELISA, IP, FC, FuncS, Neut, IF, IHC and most other immunological methods.
Pfizer is referring to this as bococizumab (Oct 2013) but that name has yet to appear in INN or USAN listsgamma2 heavy chain (1-444) [humanized VH (Homo sapiens IGHV1-46*01 (90.80%) – (IGHD) – IGHJ1*01 L123>T (113)) [8.8.11] (1- 118) – Homosapiens IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfidekappa light chain (1'- 214') [humanized V-KAPPA (Homo sapiens IGKV1 -13*02 (91.00%) – IGKJ2*01) [6.3.9] (1'-107') – Homo sapiens IGKC*01(108'-214')]; dimer (220-220":221-221":224-224":227-227") -tetrakisdisulfide
Purity
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
BACKGROUND
Antigen Description
This gene is a member of the paired box (PAX) family of transcription factors. Members of this gene family typically contain a paired box domain, an octapeptide, and a paired-type homeodomain. These genes play critical roles during fetal development and cancer growth. The specific function of the paired box 7 gene is unknown but speculated to involve tumor suppression since fusion of this gene with a forkhead domain family member has been associated with alveolar rhabdomyosarcoma. Three transcript variants encoding different isoforms have been found for this gene.